@article{JTD15955,
author = {Marius Ilie and Paul Hofman},
title = {Atezolizumab in advanced non-small cell lung cancer},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {10},
year = {2017},
keywords = {},
abstract = {Atezolizumab (Tecentriq®, MPDL3280A, Genentech, CA, USA) is a humanized IgG1 antagonist antibody to PD-L1 engineered to avoid antibody-dependent cell-mediated cytotoxicity of activated T cells that may express PD-L1 (1). It blocks directly the interaction between the PD-L1 and PD-1/B7.1 receptors activation complex, hence it activates the tumor-specific immune response, and induces tumor cell killing (1).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/15955}
}